For instance, in a pilot study, Koenig et al. (2017) showed that metformin exposure in non-diabetic patients with MCI or early signs of AD was associated with an ameliorated cognitive function, even though no changes in AD CSF biomarkers such as Aβ, Tau or p-Tau levels were observed. The gene discussed is MAPT; the disease is Alzheimer disease.